REFERENCES
1. Keefe RS, Goldberg TE,
2. Pfammatter M, Junghan UM, Brenner HD. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. Schizophr Bull. 2006;32(suppl 1):S64-S80.
3. Velligan DI, Mahurin RK,
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision.
5. Krishnadas R, Moore BP, Nayak A, Patel RR. Relationship of cognitive function in patients with schizophrenia in remission to disability: a cross-sectional study in an Indian sample. Ann Gen Psychiatry. 2007;6:19.
6. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58(1):24-32.
7. Penn DL, Sanna LJ, Roberts DL. Social cognition in schizophrenia: an overview. Schizophr Bull. 2008;34(3):408-411.
8. Ilankovic LM, Fast K, Ilankovic N, Kambeitz J, Engel R. Emotional processing in schizophrenia: the role of abstract reasoning in establishing and remembering emotional links. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
9. Cozman D, Nica S, Nemes B, Manea MM, Coman HG. Cognitive functioning in suicidal schizophrenia patients. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
10. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41-51.
11. Niendam TA, Bearden CE, Johnson JK, et al. Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res. 2006;84(1):100-111.
12. Lindenmayer JP. Increasing awareness of patient functional impairment in schizophrenia and its measurement. Primary Psychiatry. 2008;15(1):89-93.
13. Rosenheck R, Leslie D, Keefe R, et al; CATIE Study Investigators Group. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006;163(3):411-417.
14. Corbiere M, Mercier C, Lesage A. Perceptions of barriers to employment, coping efficacy, and career search efficacy in people with mental illness. J Career Assess. 2004;12(4):460-478.
15. Wykes T, Reeder C. Translating cognition to action: improving function in people with schizophrenia with cognitive rehabilitation. Schizophrenia Daily News Blog. http://www.schizophrenia.com/sznews/archives/004124.html. Accessed April 20, 2008.
16. Bowie CR, Leung WW, Reichenberg A, et al. Predicting schizophrenia patients’ real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):508-511.
17. Medalia A, Thysen J. Insight into neurocognitive dysfunction in schizophrenia. Schizophr Bull. 2008 Jan 16 [Epub ahead of print].
18. Ganguli R, Brar J, Venalapalli H, et al. Mini-Mental State Examination (MMSE) performance of partially remitted community-dwelling patients with schizophrenia. Schizophr Res. 1998;33(1-2):45-52.
19.
20. Ritsher JB. Association of Rorschach and MMPI psychosis indicators and schizophrenia spectrum diagnoses in a Russian clinical sample. Psych Res. 2004;83(1):46-63
21. Gass CS, Burda PC, Starkey TW, Dominguez F. MMPI interpretation of psychiatric inpatients: caution in making inferences about concentration and memory. J Clin Psychology. 1992;48(4):493-499.
22. Weiden PJ. Moving beyond positive symptoms: the importance of addressing cognitive and affective symptoms in the treatment of schizophrenia. Medscape Psychiatry & Mental Health. 2005;10(2). http://www.medscape.com/viewarticle/511186. Accessed June 17, 2008.
23. Neuchterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203-213.
24. Bowie CR, Reichenberg A, Patterson TL, et al. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006;163(3):418-425.
25. Galletly CA, Neaves AL, Linley A. Insight and cognition in schizophrenia. Poster presented at: 161st Annual Meeting of the American Psychiatric Association annual meeting; May 5-8, 2008;
26. Medalia A, Thysen J, Freilich B. Do people with schizophrenia who have objective cognitive impairment identify cognitive deficits on a self report measure? Schizophr Res. 2008;105(1-3):156-164.
27. Revheim N, Medalia A. The independent living scales as a measure of functional outcome for schizophrenia. Psychiatr Serv. 2004;55(9):1052-1054.
28. Kleinman L, Lieberman J, Dube S, et al. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophr Res. 2008 Nov 13. [Epub ahead of print]
29. Hill SK, Sweeney JA, Hamer RM, et al. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J Int Neuropsychol Soc. 2008;14(2):209-221.
30. Keefe RS, Poe M,
31. McEvoy JP. The costs of schizophrenia. J Clin Psychiatry. 2007;68(suppl 14):4-7.
32. Medalia A, Richardson R. What predicts a good response to cognitive remediation interventions? Schizophr Bull. 2005;31(4):942-953.
33. Schooler NR. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(suppl 5):19-23.
34. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(suppl 5):3-8.
35. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry. 2001;62(7):545-551.
36. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891.
37. Jeste SD, Patterson TL, Palmer BW, Dolder CR, Goldman S, Jeste DV. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res. 2003;63(1-2):49-58.
38. Hudson TJ, Owen RR, Thrush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2):211-216.
39. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008;161(2):235-247.
40. Keefe RS, Bilder RM, Davis SM, et al; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64(6):633-647.
41. Sergi MJ, Green MF, Widmark C, et al. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007;164(10):1585-1592.
42. Schoeman RR, Chiliza B, Emsley R. Early cognitive response to treatment in first episode psychosis. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
43. Rémillard S, Pourcher E, Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res. 2005;80(1):99-106.
44. Lee SM, Chou YH, Li MH, Wan FJ, Yen MH. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(5):1101-1107.
45. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64(10):1115-1122.
46. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1061-1071.
47. Riedel M, Müller N, Spellmann I, et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2007;257(7):402-412.
48. Voruganti LP, Awad AG, Parker G, et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res. 2007;96(1-3):146-155.
49. Meltzer HY,
50. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;187(3):312-320.
51. Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 2006;163(11):1918-1925.
52. Harvey PD, Loebel A, Kremer CM. Reduction of functional disability with atypical antipsychotic treatment: a long-term randomized clinical trial. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
53. Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr. 2006;11(12 suppl 14):1-7.
54. Ibach B, Schreiner A. Interim-analysis of a long-term treatment adherence study with LAIR and oral-second generation antipsychotics in patients with schizophrenia. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
55. Burton SC. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiatr Pract. 2005;11(6):369-378.
56. Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs. 2007;21(6):441-448.
57. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363-1370.
58. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1-3):147-161.
59. Kozma C, Dirani R, Mao L, Amatniek J, Canuso C. Change in employment status over 52 weeks in patients with schizophrenia. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
60. Kahn RS,
61. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol. 2008(6);23:343-356.
62. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2007 Dec 18 [Epub ahead of print].
63. Möller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs. 2007;67(11):1541-1566.
64. Suh SY, Lee SH. Effectiveness of long acting injectable risperidone in patients with first-episode schizophrenia. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
65. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28(2):210-213.
66. Gharabawi F, Bossie C, Turkoz I, et al. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Ment Dis. 2007;195(12):976-982.
67. Zhao Z, Pecenak J, Tuma I, et al. Improvement in personal and social functioning in schizophrenia patients treated with risperidone long acting injection: 6-month results from e-STAR. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
68. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol. 2008;23(6):325-331.
69. Möller HJ, Johnson S, Mateva T, Brecher M, Svensson O, Miller F, Meulien D; Study 146 Investigators. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol. 2008;23(2):95-105.
70. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-1257.
71. Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol. 2005;19(5 suppl):32-38.
72. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D; Study 147 Investigators. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 2008;24(1):21-32.
73. Thyssen A, Ning X, Herben V, et al. Pharmacokinetics of long-acting injectable risperidone injected in deltoid muscle compared to gluteal muscle injection in subjects with schizophrenia. Presented at the 161st Annual Meeting of the American Psychiatric Association (APA).
74. Ning X, Thyssen A, Quiroz J, et al. Tolerability and safety of long-acting injectable risperidone in chronic schizophrenia subjects using deltoid muscle as an alternative injection site. Presented at: the 161st Annual Meeting of the American Psychiatric Association (APA). May 3-8, 2008;
75. Risperdal Consta Long-Acting Injection [package insert].
76. Rathod S, Kingdon D, Weiden P, Turkington D. Cognitive-behavioral therapy for medication-resistant schizophrenia: a review. J Psychiatr Pract. 2008;14(1):22-33.
77. Pilling S, Beggington P, Kuipers E, et al. Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med. 2002;32(5):783-791.
78. Kurtz MM. Neurocognitive rehabilitation for schizophrenia. Curr Psychiatry Rep. 2003;5(4):303-310.
79.
80. Krabbendam L, Aleman A. Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies. Psychopharmacology (Berl). 2003;169(3-4):376-382.
81. Lindenmayer JP, McGurk SR, Mueser KT, et al. A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatr Serv. 2008;59(3):241-247.
82. Khan A, Lindenmayer JP, McGurk S, et al. Predictors of improvement for cognitive remediation. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
83. Cook JA, Leff S, Blyler CR, et al. Results of a multisite randomized trial of supported employment interventions for individuals with severe mental illness. Arch Gen Psychiatry. 2005;62(5):505-512.
84. Twamley EW, Jeste DV, Lehman AF. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. J Nerv Ment Dis. 2003;191(8):515-523.
85. Marwaha S, Johnson S. Views and experiences of employment among people with psychosis: a qualitative descriptive study. Int J Soc Psychiatry. 2005;51(4):302-316.
86. Marwaha S, Johnson S. Schizophrenia and employment–a review. Soc Psychiatry Psychiatr Epidemiol. 2004;39(5):337-349.
87. McGurk SR, Wykes T. Cognitive remediation and vocational rehabilitation. Psychiatr Rehabil J. 2008;31(4):350-359.
88. Awad AG,
89. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: 1. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med. 2002;32(5):763-782.
90. Bäuml J, Froböse T, Kraemer S, Rentrop M, Pitschel-Walz G. Psychoeducation; a basic psychotherapeutic intervention for patients with schizophrenia and their families. Schizophr Bull. 2006;32(suppl 1):S1-S9.
91. Combs DR, Adams SD, Penn DL, Roberts D, Tiegreen J, Stem P. Social Cognition and Interaction Training (SCIT) for inpatients with schizophrenia spectrum disorder: preliminary thoughts. Schizophr Res. 2007;91(1-3):112-116.
92. Helbling J, Ajdacic-Gross V, Lauber C, Weyermann R, Burns T, Rössler W. Attitudes to antipsychotic drugs and their side effects: a comparison between general practitioners and the general population. BMC Psychiatry. 2006;6:42.
93. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58(9):1187-1192.
94. Velligan DI, Lam YW,
95. Karow A, Pajonk FG, Reimer J, et al. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur Arch Psychiatry Clin Neurosci. 2007 Nov 13 [Epub ahead of print].
96. Davis LW, Lysaker PH. Therapeutic alliance and improvements in work performance over time in patients with schizophrenia. J Nerv Ment Dis. 2007;195(4):353-357.
97. Sapra M, Weiden PJ, Schooler NR, Goldfinger SM. Adherence to antipsychotic medications in “first-episode” schizophrenia: patients attitudes and influences. Poster presented at: 161st Annual Meeting of the American Psychiatric Association; May 5-8, 2008;
98. Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatric Serv. 2006;57(11):1636-1639.
99. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2007 Nov 28 [Epub ahead of print]
100. Bromley E. Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia. Psychiatr Serv. 2007;58(4):475-481.